Showing items 1286-1335 of 2549 (51 Page(s) Totally)
<< < 21 22 23 24 25 26 27 28 29 30 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Lin C.-C; Hsu C; Hsu C.-H; Hsu W.-L; Cheng A.-L; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:21Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Lin C.-C; Huang T.-C; Yang P.-C; CHIH-HSIN YANG; Yu C.-J; Shih J.-Y; Cheng A.-L; Hu F.-C; Kuo S.-H; Hsu C; Chih-Hsin Yang;Yang P.-C;Huang T.-C;Lin C.-C;Yu C.-J;Shih J.-Y;Cheng A.-L;Hu F.-C;Kuo S.-H;Hsu C |
| 臺大學術典藏 |
2020-05-26T09:27:21Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Chih-Hsin Yang;Cheng A.-L;Keng H.-Y;Hsu C.-H;Pu Y.-S;Lin C.-C; Lin C.-C; Pu Y.-S; Hsu C.-H; Keng H.-Y; Cheng A.-L; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:20Z |
National Center Of Excellence For Clinical Trials And Research At National Taiwan University Hospital
|
Lin C.-C; CHIH-HSIN YANG; Cheng A.-L; Chan W.-K; Ho H.-N. |
| 臺大學術典藏 |
2020-05-26T09:27:20Z |
National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital
|
Lin C.-C;Chih-Hsin Yang;Cheng A.-L;Chan W.-K;Ho N.-N.; Lin C.-C; CHIH-HSIN YANG; Cheng A.-L; Chan W.-K; Ho N.-N. |
| 臺大學術典藏 |
2020-05-26T09:27:19Z |
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer
|
Lin C.-C;Chih-Hsin Yang; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:18Z |
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
|
Lin C.-C;Hsu H.-H;Sun C.-T;Shih J.-Y;Lin Z.-Z;Yu C.-J;Chen G.G;Hsin M.K.Y;Lam K.C;Leung L;Chih-Hsin Yang;Mok T.; Lin C.-C; Hsu H.-H; Sun C.-T; Shih J.-Y; Lin Z.-Z; Yu C.-J; Chen G.G; Hsin M.K.Y; Lam K.C; Leung L; CHIH-HSIN YANG; Mok T. |
| 臺大學術典藏 |
2020-05-26T09:27:17Z |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
|
Shao Y.Y;Lin C.C;Chih-Hsin Yang; Shao Y.Y; Lin C.C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:14Z |
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations
|
Lin C.-C;Chih-Hsin Yang; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:10Z |
Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC
|
Medema R.H;Lin C.-C;Chih-Hsin Yang; Medema R.H; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:03Z |
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
|
Liao B.-C;Lin C.-C;Chih-Hsin Yang; Liao B.-C; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:02Z |
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
|
Kao H.-F;Lin C.-C;Chih-Hsin Yang; Kao H.-F; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:00Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
Lee J.-H; Lin Y.-L; Hsu W.-H; Chen H.-Y; Chang Y.-C; Yu C.-J; Shih J.-Y; Lin C.-C; Chen K.-Y; Ho C.-C; Laio W.-Y; Yang P.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:00Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S; Lin C.-C; Cho D.C; Shapiro G.I; Kwak E.L; Goel S.; Chuadhary I; Ghalib M.H; Cheng A.-L; CHIH-HSIN YANG; Coleman T; Silverman M.H; Tseng Y; Kuo M.-W; Mach W.B; Hsu S.-C |
| 臺大學術典藏 |
2020-05-26T09:26:59Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
CHIH-HSIN YANG; Kang J.H; Mok T; Ahn M.-J; Srimuninnimit V; Lin C.-C; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:57Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:55Z |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
|
Chih-Hsin Yang;Lin C.-C;Liao B.-C; Liao B.-C; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:55Z |
Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy
|
Chih-Hsin Yang;Shih J.Y;Lin C.C;Liao B.C; Liao B.C; Lin C.C; Shih J.Y; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:52Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Ho C.-C;Chang C.-H;Chen Y.-F;Lin C.-C;Lee J.-H;Liao B.-C; Liao B.-C; Lee J.-H; Lin C.-C; Chen Y.-F; Chang C.-H; Ho C.-C; Shih J.-Y; Yu C.-J; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
|
Chih-Hsin Yang;Yu C.-J;Chang Y.-C;Shih J.-Y;Ho C.-C;Lee Y.-F;Lin S.-Y;Lin C.-C;Bai Y.-Y;Liao B.-C; Liao B.-C; Bai Y.-Y; Lin C.-C; Lin S.-Y; Lee Y.-F; Ho C.-C; Shih J.-Y; Chang Y.-C; Yu C.-J; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
Safety of gefitinib in non-small cell lung cancer treatment
|
Chih-Hsin Yang;Lin C.-C;Lee J.-H;Hsiue E.H.-C; Hsiue E.H.-C; Lee J.-H; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:43Z |
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
|
Chih-Hsin Yang;Lee J.-H;Lin C.-C;Liao B.-C; Liao B.-C; Lin C.-C; Lee J.-H; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:43Z |
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer
|
Chih-Hsin Yang;Lin C.-C;Lee J.-H;Hsiue E.H.-C; Hsiue E.H.-C; Lee J.-H; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:38Z |
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component
|
J?nne P.A.;Ghiorghiu S;Cantarini M;Mann H;Lin C.-C;Hirashima T;Gold K;Novello S;Yoh K;Haggstrom D;Blackhall F;Felip E;Planchard D;Kim J.-H;Kim S.-W;Su W.-C;Sequist L.V;Ramalingam S.S;Kim D.-W;Ahn M.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Ahn M.-J; Kim D.-W; Ramalingam S.S; Sequist L.V; Su W.-C; Kim S.-W; Kim J.-H; Planchard D; Felip E; Blackhall F; Haggstrom D; Yoh K; Novello S; Gold K; Hirashima T; Lin C.-C; Mann H; Cantarini M; Ghiorghiu S; Jänne P.A. |
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
|
Chih-Hsin Yang;Lee J.-H;Lin C.-C;Liao B.-C; Liao B.-C; Lin C.-C; Lee J.-H; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:36Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Yu C.-J.;Chih-Hsin Yang;Lin C.-C;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Yu C.-J.;Chih-Hsin Yang;Shih J.-Y;Lin C.-C;Lee J.-H;Chang Y.-L;Su K.-Y;Hsu W.-H;Hsu C.-L;Tsai T.-H;Chen K.-Y;Liao W.-Y;Ho C.-C;Liao B.-C;Yang C.-Y;Lin S.-Y; Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:31Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chih-Hsin Yang;Thress K.S;Huang D.D.-R;Bai Y.-Y;Chang Y.-L;Hsieh M.-S;Su K.-Y;Tsai T.-H;Lee J.-H;Liao W.-Y;Ho C.-C;Yu C.-J;Shih J.-Y;Lin C.-C; Lin C.-C; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:29Z |
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
|
Yang P.-C.;Chih-Hsin Chih-Hsin Yang;Yu C.-J;Chang Y.-C;Shih J.-Y;Ho C.-C;Lee Y.-F;Lin S.-Y;Lin C.-C;Lee J.-H;Bai Y.-Y;Liao B.-C; Liao B.-C; Bai Y.-Y; Lee J.-H; Lin C.-C; Lin S.-Y; Lee Y.-F; Ho C.-C; Shih J.-Y; Chang Y.-C; Yu C.-J; Chih-Hsin CHIH-HSIN YANG; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:28Z |
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
|
Chih-Hsin Yang;Lin C.-C;Liao B.-C; Liao B.-C; Lin C.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:28Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non?�Small-cell Lung Cancer Patients
|
Wu T.-H; Hsiue E.H.-C; Lee J.-H; Lin C.-C; Liao W.-Y; Ho C.-C; Shih J.-Y; Yu C.-J; CHIH-HSIN YANG; Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Ho C.-C;Liao W.-Y;Lin C.-C;Lee J.-H;Hsiue E.H.-C;Wu T.-H |
| 臺大學術典藏 |
2020-05-26T09:26:22Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Doi T;Chih-Hsin Yang;Shitara K;Naito Y;Cheng A.-L;Sarashina A;Pronk L.C;Takeuchi Y;Lin C.-C.; Doi T; CHIH-HSIN YANG; Shitara K; Naito Y; Cheng A.-L; Sarashina A; Pronk L.C; Takeuchi Y; Lin C.-C. |
| 臺大學術典藏 |
2020-05-26T09:26:19Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non?�small-cell lung cancer patients
|
Yao Z.-H;Liao W.-Y;Ho C.-C;Chen K.-Y;Shih J.-Y;Chen J.-S;Lin Z.-Z;Lin C.-C;Chih-Hsin Yang;Yu C.-J.; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Lin C.-C; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:18Z |
Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study
|
Ma W.-L;Lin C.-C;Hsu F.-M;Lee J.-M;Chen J.-S;Hsieh M.-S;Chang Y.-L;Chao Y.-T;Chang C.-H;Chih-Hsin Yang; Ma W.-L; Lin C.-C; Hsu F.-M; Lee J.-M; Chen J.-S; Hsieh M.-S; Chang Y.-L; Chao Y.-T; Chang C.-H; Chih-Hsin CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:17Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y;Liao W.-Y;Ho C.-C;Chen K.-Y;Tsai T.-H;Hsu C.-L;Su K.-Y;Chang Y.-L;Wu C.-T;Hsu C.-C;Liao B.-C;Hsu W.-H;Lee J.-H;Lin C.-C;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J. |
| 臺大學術典藏 |
2020-05-26T09:26:16Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H; Chen T.W.-W; Hsu C.-H; Yen Y.-H; CHIH-HSIN YANG; Cheng A.-L; Sasaki S.-I; Chiu L.Y; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin C.-C.; Lee J.-H;Chen T.W.-W;Hsu C.-H;Yen Y.-H;Chih-Hsin Yang;Cheng A.-L;Sasaki S.-I;Chiu L.Y;Sugihara M;Ishizuka T;Oguma T;Tajima N;Lin C.-C. |
| 臺大學術典藏 |
2020-05-25T07:27:27Z |
Association between maternal shift work and infant neurodevelopmental outcomes: Results from the Taiwan Birth Cohort Study with propensity-score-matching analysis
|
Wei C.-F.;Chen M.-H.;Lin C.-C.;Yue-Liang Guo;Lin S.-J.;Liao H.-F.;Hsieh W.-S.;Chen P.-C.; Wei C.-F.; Chen M.-H.; Lin C.-C.; YUE-LIANG GUO; Lin S.-J.; Liao H.-F.; Hsieh W.-S.; Chen P.-C. |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C; Yang C.-H; YEN-SHEN LU; Lin C.-C; Bu C.-F; Yeh K.-H.; Yeh K.-H.;Bu C.-F;Lin C.-C;Yen-Shen Lu;Yang C.-H;Hsu C;Cheng A.-L;Hsu C.-H; Hsu C.-H; Cheng A.-L |
| 臺大學術典藏 |
2020-05-25T06:52:07Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C;Cheng A.-L;Hsu C.-H;Yen-Shen Lu;Hsu C;Yeh K.-H;Wu C.-Y;Huang C.-S;Yang C.-H.; Lin C.-C; Cheng A.-L; Hsu C.-H; YEN-SHEN LU; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T06:51:54Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Yen-Shen Lu;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Yang J.C.-H.; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; YEN-SHEN LU; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T02:45:41Z |
Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study
|
Cheng J.C.-H.; Lee Y.-C; Tsai Y.-C; Hsu C.-H; Feng-Ming Hsu; Lin C.-C; Lee J.-M; Chang Y.-L |
| 臺大學術典藏 |
2020-05-25T02:45:40Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C; Hsu C.-H; Cheng J.C; Huang C.-Y; Tsai Y.-C; Feng-Ming Hsu; Huang K.-H; Cheng A.-L; Pu Y.-S. |
| 臺大學術典藏 |
2020-05-25T02:45:40Z |
Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma
|
Feng-Ming Hsu;Lee J.-M;Huang P.-M;Lin C.-C;Hsu C.-H;Tsai Y.-C;Lee Y.-C;Chia-Hsien Cheng J.; Feng-Ming Hsu; Lee J.-M; Huang P.-M; Lin C.-C; Hsu C.-H; Tsai Y.-C; Lee Y.-C; Chia-Hsien Cheng J. |
| 臺大學術典藏 |
2020-05-25T02:45:37Z |
Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma
|
Wang C.-C;Cheng J.C.-H;Tsai C.-L;Lee J.-M;Huang P.-M;Lin C.-C;Hsu C.-H;Hsieh M.-S;Chang Y.-L;Feng-Ming Hsu; Wang C.-C; Cheng J.C.-H; Tsai C.-L; Lee J.-M; Huang P.-M; Lin C.-C; Hsu C.-H; Hsieh M.-S; Chang Y.-L; Feng-Ming Hsu |
| 臺大學術典藏 |
2020-05-25T02:45:35Z |
Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma
|
Guo J.-C; Huang T.-C; Lin C.-C; Hsieh M.-S; Chang C.-H; Huang P.-M; Lee J.-M; Feng-Ming Hsu; Cheng J.C.-H; Wang H.-P; Yeh K.-H; Cheng A.-L; Hsu C.-H. |
| 臺大學術典藏 |
2020-05-25T02:45:28Z |
Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
|
Lee J.-M.; Cheng J.C.-H; Hsu C.-H; Huang P.-M;Feng-Ming Hsu;Lin C.-C;Hsu C.-H;Cheng J.C.-H;Lee J.-M.; Huang P.-M; Feng-Ming Hsu; Lin C.-C |
| 臺大學術典藏 |
2020-05-25T02:45:24Z |
Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment
|
Lu S.-L;Feng-Ming Hsu;Tsai C.-L;Lee J.-M;Huang P.-M;Hsu C.-H;Lin C.-C;Chang Y.-L;Hsieh M.-S;Cheng J.C.-H.; Lu S.-L; Feng-Ming Hsu; Tsai C.-L; Lee J.-M; Huang P.-M; Hsu C.-H; Lin C.-C; Chang Y.-L; Hsieh M.-S; Cheng J.C.-H. |
| 臺大學術典藏 |
2020-05-25T02:45:22Z |
Clinical Outcomes of Up-front Surgery Versus Surgery After Induction Chemotherapy for Thymoma and Thymic Carcinoma: A Retrospective Study
|
Ma W.-L;Lin C.-C;Feng-Ming Hsu;Lee J.-M;Chen J.-S;Hsieh M.-S;Chang Y.-L;Chao Y.-T;Chang C.-H;Chih-Hsin Yang J.; Ma W.-L; Lin C.-C; Feng-Ming Hsu; Lee J.-M; Chen J.-S; Hsieh M.-S; Chang Y.-L; Chao Y.-T; Chang C.-H; Chih-Hsin Yang J. |
| 臺大學術典藏 |
2020-05-19T01:53:04Z |
Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery
|
Lee J.-M. ;Yang S.-Y. ;Yang P.-W. ;Shun C.-T. ;Wu M.-T. ;Hsu C.-H. ;Lin C.-C. ;Cheng J.-C.-H. ;Wang Y.-H. ;Chuang T.-H. ;Chen J.-S. ;Hsu H.-H. ;Pei-Ming Huang ;Kuo S.-W. ;Lee Y.-C.; Lee J.-M.; Yang S.-Y.; Yang P.-W.; Shun C.-T.; Wu M.-T.; Hsu C.-H.; Lin C.-C.; Cheng J.-C.-H.; Wang Y.-H.; Chuang T.-H.; Chen J.-S.; Hsu H.-H.; PEI-MING HUANG; Kuo S.-W.; Lee Y.-C. |
Showing items 1286-1335 of 2549 (51 Page(s) Totally)
<< < 21 22 23 24 25 26 27 28 29 30 > >>
View [10|25|50] records per page
